Abstract 2187
Background
The number of Chinese cancer survivors is increasing due to the trend of an aging population and improved cancer survival. It is urgently required to estimate the health status of cancer survivors and provide scientific evidence for future health care reform. This study aimed to evaluate the general health status of cancer survivors older than 45 years in China.
Methods
We identified cancer survivors (n = 354) and participants without cancer (n = 16,664) in the China Health and Retirement Longitudinal Study (CHARLS). Physical and mental health information collected by questionnaire were compared between cancer survivors and cancer-free controls.
Results
The mean age of cancer survivors was 61.0 years. More cancer survivors were female (68.9% vs. 52.3%, P < 0.001) and lived in a rural region (43.8% vs. 38.4%, P = 0.039) than those without cancer. Cancer survivors and participants without cancer did not show significant differences in age, marital status, education or BMI. The health status of middle-aged and older cancer survivors are shown in the table. Cancer survivors had more concomitant chronic diseases than participants without cancer (2.75 vs. 2.00, P < 0.001). The current health condition reported by cancer survivors themselves was poorer than no cancer group (3.87 vs. 3.38, P < 0.001). The daily activity score was higher in the cancer group (3.53 vs. 2.39, P < 0.001), which indicated that cancer survivors had more difficulties in their daily life than other middle-aged and older participants. There was no statistically significant difference in cognitive function between these two groups even after adjustment (12.61 vs. 12.90, P = 0.612). Cancer survivors had more depressive symptoms than participants without cancer after adjustment (10.07 vs. 8.01, P = 0.003).Table: 1649P
Health status of middle-aged and older cancer survivors and participants without cancer from the CHARLS
Characteristic | Total (N = 17,018) | Cancer survivors (n = 354) | No cancer (n = 16,664) | P value | P value† |
---|---|---|---|---|---|
Number of concomitant chronic diseases, mean ± SD | 2.02 ± 1.70 | 2.75 ± 2.13 | 2.00 ± 1.69 | <0.001 | |
Self-reported health score (1-5), mean ± SD | 3.39 ± 0.38 | 3.87 ± 0.82 | 3.38 ± 0.87 | <0.001 | <0.001 |
Daily activity, mean ± SD | 2.41 ± 3.36 | 3.53 ± 3.85 | 2.39 ± 3.35 | <0.001 | <0.001 |
Cognitive function, mean ± SD | 12.89 ± 5.69 | 12.61 ± 5.60 | 12.90 ± 5.69 | 0.629 | 0.612 |
Depression, mean ± SD | 8.05 ± 6.41 | 10.07 ± 7.06 | 8.01 ± 6.39 | <0.001 | 0.003 |
Adjusted for age, sex, region, and number of concomitant chronic diseases.
Conclusions
The health status of middle-aged and older cancer survivors is poor in China. High-quality and cost-effective supportive care for these individuals is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (No. 61435001) and CAMS Innovation Fund for Medical Sciences (No. 2016-I2M-1-001, No. 2017-I2M-4-003).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract